A systematic review of acute and long-term outcomes in patients with non-transvenous implantable cardioverter-defibrillators.

J Med EconMay 22, 2026 (epub)
Clinical ResearchCardiology

Steven Zweibel, David Lanctin, Reece Holbrook et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the outcomes of non-transvenous implantable cardioverter-defibrillators (ICDs) in adult patients with guideline-based indications. Analyzing 25 studies with 4,633 patients, the review found procedural success rates ranging from 81% to 100% and clinical defibrillation success consistently high at 95%-100%. The findings support the safety and effectiveness of non-transvenous ICDs.

Key findings

  • Procedural success rates ranged from 81% to 100%, with most studies reporting rates ≥94%.
  • Long-term complication rates were 0%-8% at 0.5-1.5 years and 1%-14% beyond 1.5 years.
  • All-cause mortality increased from 1%-5% within 6 months to 16%-26% at 4-8 years.
  • Inappropriate shock incidence ranged from 7%-13% at 1 year and 2%-18% at later timepoints.

Why it matters

Understanding the safety and effectiveness of non-transvenous ICDs is crucial for clinicians managing patients with life-threatening arrhythmias. This review provides evidence supporting their use, potentially influencing treatment decisions and patient outcomes.

Source

Published in J Med Econ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.